Kris on Oncology

• A Year of Lung Cancer Improvements, With More Work To Do   Dr Mark Kris discusses good news in lung cancer and urges efforts to improve lung cancer screening.
  Medscape Oncology, April 21, 2022
• Oncogene-Positive Lung Cancer: What Therapy to Start?   Dr Mark Kris discusses the choice between chemotherapy and targeted therapy in patients with lung cancer and oncogenic drivers.
  Medscape Oncology, April 20, 2022
• Rapid Recommendation Update From ASCO for Stage IB-IIIA NSCLC   The new recommendations include adjuvant osimertinib and atezolizumab, which can cure certain patients with stage IB to IIIA NSCLC.
  Medscape Oncology, February 08, 2022
• Alleviating Chemo-Related Nausea Is a Huge Unmet Need   We need to do more to address our patients' most concerning adverse effect, says Dr Mark Kris.
  Medscape Oncology, February 02, 2022
• ESMO 2020 ctDNA Shows Promise for Assessing Lung Cancer Treatment Response   Dr Mark Kris predicts that tumor-informed assays will soon become the standard of care.
  Medscape Oncology, January 27, 2022
• Top 5 Developments in Lung Cancer in 2021   Advances in gene targets and their treatments dominated the therapeutic landscape for 2021, says Dr Mark Kris.
  Medscape Oncology, January 04, 2022
• Pembrolizumab +/- Chemotherapy: Reading Between the Studies   Dr Mark Kris discusses how to read between the studies to determine optimal treatments for patients when clinical trial data are not available.
  Medscape Oncology, December 30, 2021
• Early Data Support Neoadjuvant Immunotherapy for NSCLC   A handful of studies on neoadjuvant immunotherapy for lung cancer are nearing completion, Mark Kris reports.
  Medscape Oncology, December 22, 2021
• Adjuvant Atezo in Stage II/IIIA Lung Cancer: A New Standard?   Dr Mark Kris discusses a recent trial demonstrating improved disease-free survival for patients with resected stage II to IIIA, PD-L1-positive lung cancer treated with atezolizumab following cisplatin-based chemotherapy.
  Medscape Oncology, December 01, 2021
• Tips to Reduce Treatment Downtime in Lung Cancer   Dr Mark Kris discusses waiting in the oncology setting, focusing on the importance of communication with colleagues and with patients.
  Medscape Oncology, November 29, 2021
• Treatment Tips for Challenging EGFR-Mutant Lung Cancers   Dr Mark Kris discusses challenges related to treating lung cancers with EGFR mutations.
  Medscape Oncology, November 23, 2021
• ASCO 2021 ASCO Lung Cancer Targeted Therapy Data Expands EGFR and MET   Some of the new targeted therapies work even when the mechanism is unknown, says Dr Kris.
  Medscape Oncology, July 29, 2021
• ASCO 2021 ASCO 2021: Best Lung Cancer IO Data   Pooled analysis supports chemo + immunotherapy for patients with PD-L1 1%-49%; immunosuppressants for adverse effects of immunotherapy; and AI predicts outcomes better than pathologic exam.
  Medscape Oncology, July 21, 2021
• ASCO 2021 ASCO Data Present 'Clear Roadmap' to Treat Locally Advanced NSCLC   'These studies point to the need for multimodality therapy for the patients with locally advanced NSCLC,' says Dr Mark Kris.
  Medscape Oncology, July 09, 2021
• Osimertinib: A Bright Spot at the End of a Dismal 2020   Approval of the first adjunctive treatment for patients with stage IB to IIIA lung cancer is a harbinger of targeted therapies to come, says Dr Mark Kris.
  Medscape Oncology, January 19, 2021
• Top 10 Advances in Thoracic Oncology in 2020   Dr Mark Kris details what he considers the 10 most important developments in lung cancer management from 2020.
  Medscape Oncology, January 19, 2021
• NCCN Guidelines Pave Way for Improving Lung Cancer Survival   Recently updated NCCN guidelines have Dr Mark Kris excited about the future of lung cancer treatment and survival.
  Medscape Oncology, January 07, 2021
• ESMO 2020 Osimertinib as Adjuvant Therapy in EGFR-Mutant Lung Cancer   Dr Mark Kris discusses how recent data presented at ESMO continue to support osimertinib as an important drug in the adjuvant setting for patients with completely resected EGFR-mutant lung cancer.
  Medscape Oncology, October 16, 2020
• ESMO 2020 An Important Negative Study for Post-op RT in Lung Cancer   With Lung ART results not showing benefit for postoperative radiotherapy in stage IIIA lung cancer, Dr Mark Kris says it can't be recommended as standard of care for all patients but may benefit some.
  Medscape Oncology, October 08, 2020
• Checkpoint Inhibitors: Sooner Than Later in Lung Cancer?   Checkpoint inhibitors may offer a 'unique opportunity' to improve the cure rate in lung cancer, says Dr Mark Kris.
  Medscape Oncology, September 14, 2020